Introduction {#sec1}
============

Rheumatoid arthritis (RA) is a chronic autoimmune disease leading to severe disability and premature mortality \[[@cit0001]\]. Although the aetiology of RA remains unclear, over the past years the significant progress in RA processes understanding has been done \[[@cit0002]--[@cit0004]\]. Measurement of disease activity became a crucial component of RA management \[[@cit0005]\]. Due to high degree of heterogeneity of RA, the assessment of disease activity requires a number of subjective and objective criteria of disease supplemented by laboratory parameters \[[@cit0006]\]. Precise disease assessment and a prediction of outcomes in reliable way would provide means for optimization of care \[[@cit0007]\]. The disease activity score (DAS) is a tool used to monitor RA activity. It combines swollen and tender joints, acute phase reactants (APR): C-reactive protein (CRP) or erythrocyte sedimentation rate (ESR) and a patient-reported measure of general health using Visual Analog Scale (VAS) \[[@cit0008]\]. Autoantibodies such as rheumatoid factor (RF) and antibodies to citrullinated protein antigens (ACPAs), the most common commercially available as anti-cyclic citrullinated peptide antibodies (anti-CCP), are used most often to confirm RA diagnosis, on occasion may be used to predict a prognosis or an organ involvement \[[@cit0009], [@cit0010]\]. Another serological marker, such as serum antinuclear antibodies (ANA) has been demonstrated to prevail in RA and they are extensively explored as laboratory tool for diagnosis and follow-up of systemic autoimmune rheumatic diseases (SARDs) \[[@cit0011], [@cit0012]\]. In the last few years, there has been demonstrated that laboratory panel used in RA monitoring may be further elucidated by a cytokine evaluation \[[@cit0013], [@cit0014]\]. Multiple studies have demonstrated that disease-related cytokines may be elevated even in healthy, asymptomatic blood donors, who have later developed RA and cytokines are considered as the potential RA biomarkers \[[@cit0013]--[@cit0015]\].

There is, as yet, insufficient evidence that any marker, in isolation or in combination can sufficiently predict disease outcome and assess early RA activity. Therefore, we undertook a prospective longitudinal study to assess the relative usefulness of available markers as prognostic and monitoring tool, and we completed it with the serum multi-cytokine evaluation.

Material and methods {#sec2}
====================

Study group {#sec2.1}
-----------

The study group constituted of 16 patients with undifferentiated arthritis (UA), who developed RA. That group was identified from a total of 121 people with suspected UA identified at Regional Hospital for Rheumatic Diseases in Sopot, Poland. All subjects underwent a wide range of laboratory tests, including: acute phase reactants (ESR, CRP), serological markers -- (RF \[immunoturbidymetric method\], anti-CCP \[electrochemiluminescence method\], antithyroglobulin antibodies (anti-TG) \[electrochemiluminescence method\], ANA-HEp2 \[immunofluorescence method\]), complete blood count (CBC), alanine aminotransferase (ALT), fasting blood glucose, aspartate aminotransferase (AST) and creatinine, serological markers of hepatitis B, hepatitis C and human immunodeficiency virus (HIV), and general urine test. Clinical assessment of their status included: tender joint count (TJC), swollen joint count (SJC), American College of Rheumatology (ACR) tender score, ACR swollen score, DAS28-CRP and VAS. Of the 121 initially identified, 58 patients with suspected UA (mean age 43.5 ±11.9 \[mean ± SD\] years) met following criteria:

1.  had a minimum of one peripheral joint inflammation lasting from 2 to 4 months;

2.  were not treated with disease modifying anti-rheumatic drugs (DMARDs), biological treatment (bDMARDs) nor steroids;

3.  did not fulfil any of the American College of Rheumatology/European League Against Rheumatism Collaborative Initiative (ACR/EULAR) classification criteria for any specific rheumatic disease at the time of enrolment; thus, they were diagnosed as UA.

The final diagnoses and the introduction of DMARD treatment (sulfasalazine \[SSZ\], methotrexate \[MTX\] or Arechin) were made during 6 months since first visit.

From total of 58 UA patients, 20 were classified as having rheumatoid arthritis (UA→RA) and 16 of them completed the whole study procedure, participating in another two follow-up visits which occurred over three and six months since the final diagnosis. These patients constituted the study group.

The control group consisted of 16 clinically healthy volunteers, without any symptoms of joint inflammation, with no autoimmune or chronic inflammatory diseases in personal or family history. Healthy volunteers were not blood donors and were recruited among Pomeranians, Poland. The control individuals were examined by the same rheumatologists and they had undergone the same range of laboratory tests as the patients. The demographical and clinical characteristics of UA→RA and healthy volunteers groups are presented in [Table 1](#t0001){ref-type="table"}.

###### 

Demographical and clinical characteristic of groups and treatment used in UA→RA group. Differences in laboratory parameters between UA→RA and healthy control groups were considered to be statistically significant at *p* \< 0.05

  --------------------------------------------------------------------------------------------------------------------
  Parameter            UA→RA                          Control group       *p*                                     
  -------------------- ------------------------------ ------------------- ------------------- ------------------- ----
  individuals, N       16                             16                                                          

  ages, years,         46.5\                          37.3\                                                       
                       (18-61)                        (26-49)                                                     

  female, N            14                             16                                                          

  treatment, N         MTX, 5\                                                                                    
                       MTX, NSAID, 3\                                                                             
                       SSZ, 2\                                                                                    
                       SSZ, MTX, 2\                                                                               
                       NSAID, Arechin, 1\                                                                         
                       NSAID, Arechin, Metypred, 1\                                                               
                       NSAID, 2                                                                                   

                       Visit 1                        Visit 2             Visit 3                                 

  DAS28                4.66\                          3.95\               2.93\                                   
                       (3.54-6.26)                    (1.34-5.36)         (1.23-4.65)                             

  WBC, G/l             7.2 (4.2-12.3)                 6.3 (4.3-10.8)      6.0 (4.6-9.3)       6.2 (3.6-11.1)      NS

  RBC, T/l             4.5 (4.2-5.0)                  4.5 (3.8-5.1)       4.4 (3.9-4.8)       4.5 (4.0-5.3)       NS

  Hgb, g/dl            13.0 (10.9-14.1)               13.3 (11.6-14.5)    13.4 (10.5-14.8)    13.5 (11.5-15)      NS

  \% Hct               38.9 (34.5-42)                 39.4 (35.0-41.8)    39.4 (33.0-42.5)    39.5 (34-43.3)      NS

  MCV, fl              87.1 (77.8-94.1)               88.6 (81.9-92.7)    89.5 (80.5-92.6)    86.4 (76.7-94.5)    NS

  MCH, pg              29.4 (24.8-31.8)               29.5 (26.7-32.7)    30.2 (25.6-32.1)    29.7 (25.3-33.2)    NS

  MCHC, g/dl           33.6 (31.6-34.9)               33.5 (32.5-35.4)    34.2 (31.8-35.4)    34.15 (33-35.1)     NS

  \% RDW               13.3 (12.6-23.2)               14.3 (12.5-16.3)    13.7 (12.9-17.0)    12.8 (11.8-15.7)    NS

  PLT, G/l             287 (174-501)                  260 (176-399)       271 (230-424.0)     283 (221-344)       NS

  MPV, fl              10.6 (10.1-12.4)               10.7 (9.8-12.0)     10.7 (9.5-12.4)     10.4 (9.5-12.5)     NS

  neutrophils, G/l\    5.0 ( 2.1-8.8)\                3.7 (2.1-6.5)\      3.7 (2.7-6.2)\      3.5 (1.5-8.5)\      NS
  %                    66.7 (45.4-71.4)               58.7 (49.2-74.0)    60.6 (49.9-67.1)    57.0 (36.6-76.5)    

  lymphocytes, G/l\    1.7 (1.1-2.9)\                 1.8 (1.3-3.5)\      1.8 (1.1-2.8)\      1.9 (0.7-3.8)\      NS
  %                    23.1 (17.2-43)                 31.1 (19.8-42.1)    29.4 (23.2-38.2)    30.9 (15-47.8)      

  monocytes, G/l\      0.5 (0.3-1.1)\                 0.5 (0.3-1.0)\      0.5 (0.3-1.0)\      0.5 (0.1-0.8)\      NS
  %                    7.7 (4.9-10.1)                 8.3 (5.6-13.2)      8.2 (5.5-11.9)      7.1 (2.9-11.6)      

  eosinophiles, G/l\   0.15 (0.04-0.38)\              0.13 (0.03-0.33)\   0.09 (0.02-0.33)\   0.12 (0.03-0.30)\   NS
  %                    2.6 (0.6-4.3)                  1.8 (0.5-5.7)       1.7 (0.4-6.5)       2.3 (0.4- 5.2)      

  basophiles, G/l\     0.02 (0.01-0.07)\              0.02 (0.00-0.06)\   0.02 (0.01-0.05)\   0.02 (0.01-0.05)\   NS
  %                    0.25 (0.2-1.00)                0.3 (0.0-0.7)       0.4 (0.1-0.6)       0.25 (0.1-0.7)      

  ALT, U/l             18.5 (8-32)                    23 (10-53)          19 (9-35)           15 (8-91)           NS

  AST, U/l             20.5 (11-30)                   20 (11-36)          20 (10-31)          19 (11-43)          NS

  HbsAg, N             0                              0                   0                   0                   NS

  anti-HCV, N          0                              0                   0                   0                   NS

  ESR, N (mm/h)        22 (5-49)                      12 (3-33)           15 (5-49)           15.5 (2-41)         NS

  CRP, g/l             1.7 (0.5-17.6)                 1.4 (\< 0.3-9.4)    3.1 (\< 0.3-8.9)    1.5 (\< 0.3-15.1)   NS

  creatinine, mg/dl    0.7 (0.6-0.97)                 0.8 (0.5-1.1)       0.74 (0.6-1.0)      0.81 (0.67-0.9)     NS

  eGFR, ml/min         \> 60                          \> 60               \> 60               \> 60               NS

  anti-HIV,\           0                                                                      0                   NS
  N (positive)                                                                                                    
  --------------------------------------------------------------------------------------------------------------------

Data are presented as median (min.-max.) or number of individuals.

ACR -- American College of Rheumatology; ALT -- alanine aminotransferase; Anti- HCV -- antibodies against hepatitis C; AST -- aspartate aminotransferase; CRP -- C-reactive protein; DAS -- Disease Activity Score; ESR -- erythrocyte sedimentation rate; MDRD-eGFR -- Modification of Diet in Renal Disease formula of estimated glomerular filtration rate; HbsAg -- surface antigen of hepatitis B; Hct -- hematocrit; Hgb -- hemoglobin; HIV -- human immunodeficiency virus; MCH -- mean corpuscular haemoglobin; MCHC -- mean corpuscular haemoglobin concentration; MCV -- mean corpuscular volume; MPV -- mean platelet volume; MTX -- methotrexate; NS -- not statistically significant, NSAID -- non-steroid anti-inflammatory drugs; PLT -- platelets; RDW -- red cell distribution width; RBC -- red blood cells; SJC -- swollen joint count; SSZ -- sulfasalazine; TJC -- tender joint count; WBC -- white blood cells

The study was approved by the Local Independent Committee for Ethics in Scientific Research at the Medical University of Gdansk and the written consent was obtained from all patients and controls.

Measurement of cytokines {#sec2.2}
------------------------

Cytokines in sera were assayed using flow cytometric bead array BD ^TM^ CBA Flex Sets (BD Bioscience, USA). Blood sera from UA→RA patients and healthy subjects were collected and centrifuged at 4000 rpm for 5 minutes. These serum samples were kept frozen at --80°C until further processing for the simultaneous quantification of 7 cytokines: interferon-γ (IFN-γ), interleukin-10 (IL-10), tumour necrosis factor (TNF), interleukin-17A (IL-17A), interleukin-6 (IL-6), interleukin-1b (IL-1b), interleukin-2 (IL-2). The assay was performed according to the manufacturer's instructions. Briefly, antibody-coupled beads specific for single cytokines were mixed and incubated with 50 μl of sera. Then they were incubated with mixture of detection antibodies conjugated to reporter molecules (phycoerithrin -- PE). Following incubation and subsequent washing, the samples were acquired using a flow cytometer (BD FACS Array, BD Biosciences, USA).

Data analysis {#sec2.3}
-------------

The Kolmogorov-Smirnov test revealed no-normal distribution of the parameters. The differences between cytokine and acute phase reactant concentrations before and after diagnosis and introduction of treatment were calculated by the Wilcoxon test. The significance of differences between cytokine levels in groups of UA→RA patients and healthy controls were calculated by *U* Mann-Whitney test. The correlations between the concentrations of each parameter were tested using Spearman correlation. Differences for all were considered to be significant at *p* \< 0.05. GraphPad Prism version 6.00 for Windows (GraphPad Software, La Jolla California USA, [www.graphpad.com](http://www.graphpad.com)) and Statistica™ 10 (StatSoft analysing software, Poland) were used for all statistical analyses and plots.

Results {#sec3}
=======

Demographic and clinical data {#sec3.1}
-----------------------------

In the group of patients with arthralgia (*n* = 121), 47.9% (*n* = 58) developed UA and 16.5% (*n* = 20) were diagnosed as RA, during 6 months from the first rheumatology visit. Thus, patients developing RA constituted 34.5% of patients with UA. Characteristic of study group (16 patients developing RA and participating in the follow-up studies after 3 and 6 months since diagnosis) is showed in [Table 1](#t0001){ref-type="table"}. The ratio of female to male in the UA→RA group was 14 : 2. Since diagnose as RA, the patients had introduced steroids, DMARD or non-steroid anti-inflammatory drugs (NSAID). The DAS28 decreased significantly after 3 and 6 months since diagnosis and introduction of treatment (second and third visit, respectively; [Fig. 2](#f0002){ref-type="fig"}). Considering DAS28 \< 2.6 as cut point of clinical remission and DAS28 ≤ 3.2 as low disease activity and DAS28 \> 3.2 high disease activity \[[@cit0016]\] (1), all patients had high disease activity in the first visit, in the second visit 4 of them were in the remission, while 8 patients were in a remission at the third visit. The median value of laboratory tests such as complete blood counts (CBC), hepatic and renal laboratory profiles or CRP in both groups were within the normal ranges and they did not differ statistically significantly. However, the first UA→RA visit characterized slightly higher median number of WBC and lower median values of Hct and Hgb in comparison to the healthy group. The virology status (HIV, HBV, HCV) was negative in both groups.

Autoantibody profile in prediction of disease progression {#sec3.2}
---------------------------------------------------------

Baseline autoantibody evaluation of patients was done at the time of entry, 6 to 12 months before established diagnosis.

We did not observed any DAS28 difference between groups of RF-positive, anti-CCP- positive or ANA-HEp-2-positive patients and respective seronegative patients within any visit. However, comparing groups of anti-CCP and RF-double negative and anti-CCP and RF-double positive, the trend (no statistically significant) of sooner clinical improvement was visible in the second above- mentioned group ([Fig. 1](#f0001){ref-type="fig"}).

![Visit-to-visit changes of DAS28 in groups of anti-CCP- and RF-positive (A) and -negative patients (B). Each symbol and line represents the DAS28 score of one UA→RA patient](CEJI-42-30870-g001){#f0001}

![Visit-to-visit changes of DAS28, serum inflammatory parameters (upper panel) and cytokine concentrations (lower panel). Each dot represents a result obtained for a single patient and medians are represented as horizontal lines](CEJI-42-30870-g002){#f0002}

Regarding 4 patients being in the remission during the second visit (after 3 months since diagnosis and introduction of treatment), 3 of them were anti-CCP and RF positive and 1 patient was anti-CCP positive. In the group of 8 patients being in remission in the third visit (6 months since the diagnosis and introduction of treatment), 3 of them had positive results of both RF and anti-CCP, 3 patients were RF- and- anti-CCP-negative and 2 patients had positive results of anti-CCP.

The serum cytokine levels in patients and controls {#sec3.3}
--------------------------------------------------

The statistically higher serum cytokine levels in UA→RA patients than healthy controls were noted on UA→RA patients' first and second visit, while at the third visit, after 6 months from diagnosis and introduction of treatment, no statistically significant differences were observed ([Table 2](#t0002){ref-type="table"}).

###### 

Serum cytokine concentrations in UA→RA and healthy control groups. Data are presented as median \[min.-max.\] (pg/ml); statistical significance of differences of cytokine concentrations between healthy controls and UA→RA patients were calculated by U-Mann Whitney test. Differences were considered to be statistically significant at *p* \< 0.05

  Visit   Serum cytokine levels   UA→RA patients     Control group     *p*
  ------- ----------------------- ------------------ ----------------- ---------
  I       IFN-γ                   1.1 (0.8-12.4)     1.0 (0.7-1.2)     \< 0.05
  II      1.1 (0.5-6.9)                              0.08              
  III     0.9 (0.8-2.6)                              0.79              
  I       IL-2                    2.9 (2.4-17)       2.5(2.1-4.1)      \< 0.05
  II      2.9 (2.4-17.1)                             \< 0.05           
  III     2.4 (1.9-26.2)                             0.36              
  I       IL-6                    8.0 (1.9-37)       3.7 (1.8-6.1)     \< 0.05
  II      4.5 (1.9-29.1)                             \< 0.05           
  III     2.7 (1.7-18.0)                             0.72              
  I       IL-10                   3.3 (1.6-21.8)     2.7 (1.4-4.1)     \< 0.05
  II      3.1 (1.4-21.7)                             \< 0.05           
  III     2.1 (1.4-13.6)                             0.49              
  I       IL-17A                  15.9 (7.8-139.6)   14.6 (4.2-15.7)   \< 0.05
  II      15.8 (8.5-84.5)                            \< 0.05           
  III     7.2 (3.4-112.9)                            0.36              
  I       IL-1β                   2.6 (1.9-17.1)     2.4 (1.3-3.0)     0.11
  II      2.6 (1.8-21.9)                             0.13              
  III     2.2 (1.4-31-7)                             1.0               
  I       TNF                     2.9 (1.2-37.6)     2.8 (1.6-3.6)     0.22
  II      3.5 (1.8-21.3)                             \< 0.05           
  III     2.8 (1.3-42.9)                             0.81              

Inflammatory markers and cytokine profile in the course of disease {#sec3.4}
------------------------------------------------------------------

We observed statistically significant reduction of ESR after 3 and 6 months since the introduction of treatment (ESR exceeded normal range: 11/16 in first visit, 6/16 in second visit, 7/16 in third visit) while CRP level reduction was slight, no statistically significant (CRP exceeded normal range: 3/16 in first visit, 3/16 in second visit, 1/16 in third visit). There was no significant correlation between the ESR and hematocrit (Hct) values. Serum cytokine profile changed after 6 months since diagnosis and introduction of treatment. We noticed statistically significant reduction of IL-10, IL-6 and IL-17A between first visit and third visit. No differences were observed for second visit, 3 months of treatment were not sufficient for serum cytokine reduction. The visit-to-visit change of DAS28, APR and cytokine concentrations with *p*-values for that statistically significant are shown in [Fig. 2](#f0002){ref-type="fig"}.

Correlation of cytokines, autoantibodies, inflammatory reactants and disease activity scores {#sec3.5}
--------------------------------------------------------------------------------------------

To assess the value of clinical and biological markers in UA progressing to RA we checked the correlation between clinical activities DAS28, acute phase reactants, autoantibody and cytokine levels ([Table 3](#t0003){ref-type="table"}).

###### 

Correlation matrix of cytokines, inflammatory markers, autoantibodies and clinical scores in UA→RA (A) and correlation matrix of cytokines in healthy controls (B). The colour scale indicating correlation coefficients (r-values) is under the table. Red shades symbolize positive correlation, green shades -- negative correlation. Included numbers are correlation coefficients (r-values) for testing statistically significant (p \< 0.05)

![](CEJI-42-30870-g003a)

![](CEJI-42-30870-g003b)

No correlation of DAS28 and any parameter were observed for the first visit. The third visit characterized positive correlation of DAS28 with CRP (*r* = 0.532, *p* \< 0.05), and IL-6 (*r* = 0.727, *p* \< 0.05).

Regarding inflammatory markers, we noted positive correlation between ESR and CRP in each visit. The positive correlations between ESR and IL-1b (*r* = 0.579, *p* \< 0.05) as well as CRP and IL-1b (*r* = 0.642, *p* \< 0.05) were observed in the second visit. In the third visit, there was a positive correlation between ESR and IL-6 (*r* = 0.548, *p* \< 0.05).

We observed multiple correlations between serum cytokine levels. However, only positive correlation between IL-6 and IL-10 was observed during each visit (*r* = 0.826, 0.829, 0.759, *p* \< 0.05 respectively). The positive correlation between IL-6 and IL-17A was noted in first and second visit (*r* = 0.824, 0.774, *p* \< 0.05).

The autoantibody profile performed after patients were included into UA cohort, did not correlate with any inflammatory and cytokine parameters at the first visit.

Discussion {#sec4}
==========

In the clinical practice, patients with UA are those patients with the potential for development of persistent inflammatory arthritis, including RA, but in whom a recognized clinical pattern does not exist \[[@cit0017]\]. The proportion of patients with UA developing RA within 1 year, according different data varied from 6% to 55% \[[@cit0017], [@cit0018]\]. Our study performed according to the 2010 ACR/EULAR criteria for rheumatoid arthritis in the Polish Pomeranian population showed, that 34.5% of patients with UA developed RA.

Successful management of RA depends upon control of disease exacerbation use of DMARDs, NSAIDS and corticosteroids. Several studies have showed a beneficial effect of the early treatment of RA to achieve better results \[[@cit0017], [@cit0019], [@cit0020]\]. However, in the clinical practice, an estimation of disease activity poses essential point in a planning of therapeutic strategy- its introduction and optimization. It has been showed that during DMARDs treatment, a joint destruction may continue to progress, despite both improvement in clinical parameters and persistent reduction of ESR \[[@cit0021]\]. Therefore, it is vital to identify the parameters that can accurately indicate disease activity and predict progression of disease over time. In our study we used common clinical and laboratory parameters for monitoring of RA activity and we completed them with circulating cytokines as new potential biomarkers. Selected range of biomarkers are involved in systemic inflammation and autoimmune processes, leading to synovial hyperplasia with inflammatory cell infiltration, angiogenesis and cartilage erosion \[[@cit0022]\].

Our study documents the clinical and health status of UA patients progressing to RA. The routine laboratory measures indicated strong similarities of UA→RA to healthy individuals. That lacks of significant differences in basic laboratory profile along with high DAS28 values suggest the necessity of considering potential application of other parameters in early RA diagnosis. In our study we used DAS28 based on CRP. We observed that the introduction of treatment led to significant reduction of DAS28, one-half of patients received remission after 6 months since diagnosis and introduction of treatment. It stays in agreement that DAS28 is a useful tool assessing a disease activity \[[@cit0007], [@cit0008]\]. However, DAS28 correlated only with CRP and IL-6 levels in the third visit. Available data suggest significant positive correlation of DAS28 with CRP, IL-6, TNF and negative correlation with IL-10 in patients with already diagnosed RA \[[@cit0023]\]. This discrepancy may be dependent on the different patient cohort, in our study the patients were examined at the stage of UA, and some of them developed RA within 3-6 months after the studies were performed.

We checked if the autoantibody profile is connected with the disease course. Our analysis did not confirm that the patients positive to anti-CCP or RF differ in disease course or a response to treatment within 6 months of treatment. However, the more aggressive treatment introduced in the group of patients with positive anti-CCP and RF results comparing to the treatment applied in group of anti-CCP and RF-negative patients generally resulted in sooner clinical improvement in the first above- mentioned group. The study of Vittecoq et al. revealed the association of high level of RF with the presence of aggressive disease in RA during the longer observation \[[@cit0024]\]. Rantapää-Dahlqvist *et al*. showed that anti-CCP positive results can predate the onset of symptoms and they can be used as markers of the progression and prognosis of the disease \[[@cit0025]\].

The limited data concerning ANA-HEp-2 profile of RA patients suggest that those antibodies can be used to predict the development of autoimmune rheumatic disease \[[@cit0009], [@cit0012], [@cit0026], [@cit0027]\]. In our study we did not find any difference in DAS28 score and DAS28 reduction between ANA-HEp2 positive and negative patients. However, the positive correlation of ANA-HEp-2 initial titre and DAS28 in second visit was observed, which suggests more severe course of disease among ANA positive patients.

We supplemented current study with the circulating cytokine profiling. Cytokines are commonly considered as biomarkers of RA and tool for RA monitoring \[[@cit0028]--[@cit0033]\]**.** We demonstrated that cytokine deregulation is initialized at a very early UA stage, before fulfilling all RA classification diagnostic criteria and that the treatment introduction attenuates it. In the light of well documented impact of medication on cytokine milieu, in the current study the cytokine rebalance in time should be consider together with an impact of the medication implied. We find correlations between measured cytokines, which was a confirmation of previous reports \[[@cit0028]\]. However, beside the positive correlation of IL-1b with CRP in second visit and positive correlation of IL-6 with ESR in third visit, in the majority, cytokine levels did not correlated with CRP nor ESR. The cytokines and autoantibodies interplay in holistic pathophysiological model of RA development is suggested by positive correlations of serum cytokines after 6 months from diagnosis with anti-CCP and RF initial values.
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